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ORIGINAL ARTICLE
Lower Rates of Heart Failure and All-Cause 
Hospitalizations During Pulmonary Artery 
Pressure-Guided Therapy for Ambulatory Heart 
Failure
One-Year Outcomes From the CardioMEMS Post-Approval Study
David M. Shavelle , MD; Akshay S. Desai, MD, MPH; William T. Abraham, MD; Robert C. Bourge, MD; Nirav Raval, MD;  
Lisa D. Rathman, NP; J. Thomas Heywood, MD; Rita A. Jermyn, MD; Jamie Pelzel, MD; Orvar T. Jonsson, MD;  
Maria Rosa Costanzo, MD; John D. Henderson, MS; Marie-Elena Brett, PhD; Philip B. Adamson, MD; Lynne W. Stevenson, MD;  
for the CardioMEMS Post-Approval Study Investigators
BACKGROUND: Ambulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients 
with New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months. The 
objective of this study was to assess the efficacy and safety of PA pressure-guided therapy in routine clinical practice with 
special focus on subgroups defined by sex, race, and ejection fraction.
METHODS: This multi-center, prospective, open-label, observational, single-arm trial of 1200 patients across 104 centers within the 
United States with New York Heart Association class III HF and a prior HFH within 12 months evaluated patients undergoing 
PA pressure sensor implantation between September 1, 2014, and October 11, 2017. The primary efficacy outcome was the 
difference between rates of adjudicated HFH 1 year after compared with the 1 year before sensor implantation. Safety end points 
were freedom from device- or system-related complications at 2 years and freedom from pressure sensor failure at 2 years.
RESULTS: Mean age for the population was 69 years, 37.7% were women, 17.2% were non-White, and 46.8% had preserved 
ejection fraction. During the year after sensor implantation, the mean rate of daily pressure transmission was 76±24% and PA 
pressures declined significantly. The rate of HFH was significantly lower at 1 year compared with the year before implantation 
(0.54 versus 1.25 events/patient-years, hazard ratio 0.43 [95% CI, 0.39–0.47], P<0.0001). The rate of all-cause hospitalization 
was also lower following sensor implantation (1.67 versus 2.28 events/patient-years, hazard ratio 0.73 [95% CI, 0.68–0.78], 
P<0.0001). Results were consistent across subgroups defined by ejection fraction, sex, race, cause of cardiomyopathy, 
presence/absence of implantable cardiac defibrillator or cardiac resynchronization therapy and ejection fraction. Freedom from 
device- or system-related complications was 99.6%, and freedom from pressure sensor failure was 99.9% at 1 year.
CONCLUSIONS: In routine clinical practice as in clinical trials, PA pressure-guided therapy for HF was associated with lower PA 
pressures, lower rates of HFH and all-cause hospitalization, and low rates of adverse events across a broad range of patients 
with symptomatic HF and prior HFH.
REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02279888.
Key Words: heart failure ◼ hemodynamics ◼ population ◼ pressure ◼ pulmonary artery
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Heart failure (HF) is the primary hospital admitting diagnosis for 1 million patients and a secondary diagnosis for 2 million patients annually within the 
United States.1,2 Despite increasingly effective medical 
therapy, the burden of HF remains high, predominantly 
driven by symptoms of worsening congestion during a 
progressive rise in cardiac filling pressures. Traditional 
disease management for reducing HFH has focused on 
surveillance of weight, vital signs, and clinical symptoms 
to detect decompensation in time to avert hospitaliza-
tion. However, enhanced surveillance of these signs 
using telemonitoring strategies in randomized trials has 
consistently shown no incremental benefit over routine 
clinic-based care.3–5 Since hemodynamic changes occur 
weeks in advance of the signs and symptoms that prompt 
HFH, implantable hemodynamic monitoring may be a 
superior approach to the detection of impending conges-
tion.6 Therapy guided by remote monitoring of pulmonary 
artery (PA) pressures in the randomized CHAMPION trial 
(CardioMEMS Heart Sensor Allows Monitoring of Pres-
sure to Improve Outcomes in New York Heart Associa-
tion Class III Heart Failure Patients) resulted in a 37% 
reduction in HFH rates and a 26% relative risk reduction 
in all-cause hospitalization (ACH).7,8 In 2014, the Federal 
Drug Agency approved the CardioMEMS PA pressure 
sensor for clinical use in patients with chronic HF, New 
York Heart Association class III symptoms, and prior HFH 
within 12 months. Approval of the device for clinical use 
was contingent upon conduct of the CardioMEMS Post-
Approval Study in 1200 patients to confirm the effective-
ness and safety of PA pressure-guided therapy in clinical 
practice and in clinical subgroups underrepresented in 
the CHAMPION trial, including women, Blacks, patients 
with preserved ejection fraction (EF) and those with car-
diac resynchronization therapy and defibrillator devices. 
In this article, we report the principal 1-year efficacy and 
safety results of the CardioMEMS Post-Approval Study.
METHODS
Trial Design
The CardioMEMS Post-Approval Study was a multi-center, pro-
spective, open-label, single-arm trial evaluating the use of PA 
pressure-guided therapy in routine clinical practice.
Informed Consent and Study Protocol
The trial was reviewed and approved by an institutional review 
board at each participating center. The trial was conducted 
according to the Guidelines for Good Clinical Practice in 
Clinical Trials9 and the principles of Declaration of Helsinki.10 
Local investigators performed the screening and informed 
Nonstandard Abbreviations and Acronyms
ACE angiotensin-converting enzyme
ACH all-cause hospitalization
ARB angiotensin receptor blocker
ARNI angiotensin receptor–neprilysin 
inhibitor
AUC area under the curve
CHAMP-HF  Change the Management of 
Patients With Heart Failure
CHAMPION  CardioMEMS Heart Sensor Allows 
Monitoring of Pressure to Improve 
Outcomes in New York Heart Asso-
ciation Class III Heart Failure Patients
COAPT  Cardiovascular Outcomes Assess-
ment of the MitraClip Percutaneous 
Therapy for Heart Failure Patients 
With Functional Mitral Regurgitation
COMPASS-HF  Chronicle Offers Management to 
Patients With Advanced Signs and 
Symptoms of Heart Failure
EF ejection fraction
HF heart failure
HFH heart failure hospitalization
HFpEF HF with preserved ejection fraction




• The Post-Approval Study of 1200 patients in mul-
tiple practice settings demonstrated a 57% reduc-
tion in risk of heart failure hospitalization (HFH) and 
a 27% reduction in all-cause hospitalizations during 
the year after implantation of the CardioMEMS pul-
monary artery pressure sensor.
• HFH reduction was at least 50% in patients with 
ejection fraction >0.50 and across subgroups for 
race, sex, and HF cause.
• Pulmonary artery pressures declined during the 
year with the most significant decline for those with 
the highest baseline pulmonary artery pressures.
• Median pressure transmission rate was 85% daily 
and 100% weekly; freedom from device complica-
tions or sensor failure was over 99%.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The strategy of pulmonary artery pressure-guided 
HF management for patients with class III HF and 
prior HFH consistently reduced HFH and all-cause 
hospitalization when translated into clinical practice 
settings.
• This 1200-patient study provides generalizabil-
ity that patient compliance with transmission is 
high and benefit to reduce HFH by 50% can be 
achieved, regardless of ejection fraction, sex, or 
race.
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consent process. All participants provided written informed 
consent. Patients were initially evaluated for study eligibility at 
a screening visit and then returned for a baseline visit where a 
standard right heart catheterization procedure was performed 
with assessment of hemodynamics and PA sensor implanta-
tion. Patients returned for study visits at 1, 6, and 12 months. 
Additional details about the study protocol are provided in the 
Data Supplement. An independent clinical events committee 
adjudicated all hospitalizations and safety end points including 
associated adverse events. Hospitalizations were classified as 
HFH or ACH according to the definitions provided in the Data 
Supplement.
Participants and Eligibility Criteria
Patients with chronic HF, New York Heart Association class III 
symptoms and a prior HFH within 12 months, regardless of EF, 
were eligible for participation. Patients with HF with reduced 
ejection fraction (HFrEF) were required to be receiving a beta 
blocker for 3 months and an ACE (angiotensin-converting 
enzyme) inhibitor or ARB (angiotensin receptor blocker) for 1 
month unless the investigator deemed the patient to be intoler-
ant to β-blockers, ACE inhibitors, or ARB. Patients with body 
mass index >35 kg/m2 were required to have a chest circum-
ference <65 inches measured at the axillary level. The target PA 
branch for pressure sensor implantation was required to have 
a diameter ≥7 mm. Key exclusion criteria included active infec-
tion, history of recurrent (>1) pulmonary embolism or deep vein 
thrombosis, inability to tolerate right heart catheterization, major 
cardiovascular event (eg, myocardial infarction, open heart sur-
gery, stroke, etc) within the previous 2 months, cardiac resyn-
chronization therapy implanted within the previous 3 months, 
glomerular filtration rate <25 mL/min per 1.73 m2 (obtained 
within 2 weeks of pressure sensor implant), nonresponsive-
ness to diuretic therapy or need for chronic dialysis, congenital 
heart disease or mechanical right heart valve, anticipated need 
to undergo heart transplantation or surgical ventricular assist 
device within the next 6 months, known coagulation disorders 
and hypersensitivity or allergy to aspirin, and clopidogrel.
Setting
The participants were enrolled at 104 hospitals in the United 
States, 35% of which were academic medical centers. 
Enrollment started on September 1, 2014, and the last partici-
pant was enrolled on October 11, 2017.
Study Population
Consent was obtained from and implants were attempted 
in 1214 patients (Figure 1). Unsuccessful pressure sensor 
implantation occurred in 14 patients, who were followed for 
30 days for safety events. The 6-month visit was completed 
in 1013 patients and the 12-month visit was completed in 
875 patients. The final patient completed 1-year follow-up in 
October 2018.
Treatment
At the baseline study visit, right heart catheterization, assess-
ment of hemodynamics, and pressure sensor implantation were 
performed. Patients were instructed to transmit PA pressures 
daily. Physicians were instructed to use PA pressure goals 
to guide therapy even in the absence of change in weight or 
symptoms. Therapy could be further adjusted based on symp-
toms, weight change, or examination in clinic. Physicians were 
instructed to adjust medical therapy to maintain PA pressures 
within the euvolemic range. The euvolemic range was gener-
ally set at the following PA pressure ranges: PA systolic 15 to 
35 mm Hg, PA diastolic 8 to 20 mm Hg, and PA mean 10 to 
25 mm Hg. The difference between PA diastolic and pulmonary 
capillary wedge pressure at the time of right heart catheter-
ization was a factor considered in setting the target range of 
PA pressures. Elevation of PA pressures above the euvolemic 
range was considered a volume overloaded state (hypervol-
emic), for which physicians were advised to increase diuret-
ics and add nitrates or other vasodilators (Data Supplement). 
A decrease in PA pressures below the euvolemic range was 
considered a volume-depletion event (hypovolemic) and physi-
cians were advised to decrease diuretics (Data Supplement).
Outcomes
The methods for assessment of the primary and secondary out-
comes are described in the Data Supplement.
Primary Outcome
The primary effectiveness end point was the annualized HFH 
rate at year 1, compared with the HFH rate in the year before 
enrollment. Prespecified subgroups included sex, race/ethnic-
ity, cause of cardiomyopathy, presence or absence of implant-
able cardiac defibrillator/cardiac resynchronization therapy 
defibrillator device, and EF ranges (EF <40%, 40% ≤ EF ≤ 
50%, and EF >50%). The primary safety end points were (1) 
freedom from device- or system-related complications at 2 
years and (2) freedom from pressure sensor failure at 2 years. 
As 2-year follow-up is not yet concluded, we report here the pri-
mary effectiveness data and the corresponding primary safety 
end points at 1 year. A device- or system-related complication 
was defined as an adverse event that was related or was pos-
sibly related to the system and resulted in at least one of the 
following: treatment with invasive means other than intramus-
cular medication or right heart catheterization, death or explant 
of device. Pressure sensor failure was defined if no readings 
could be obtained from the device after troubleshooting the 
system to rule out problems with the external electronics.
Secondary Outcomes
Additional end points included ACHs, mortality rate at 1 year, 
patient compliance with pressure transmission, and PA pres-
sure change over time. PA pressure change over time was 
evaluated using the area under the curve (AUC) methodology 
to estimate the total increase (or decrease) in mean PA pres-
sure (mm Hg day) during the 1-year period relative to the first 
week of ambulatory pressures.7,11 This method quantifies the 
frequency and duration of time that a patient spends at a pres-
sure lower (or higher) than their baseline mean PA pressure.
Adverse Events
Adverse events and their definitions are listed in the Data 
Supplement. All of the adverse events were adjudicated by an 
independent clinical events committee.
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Trial Coordination
An independent clinical events committee and steering com-
mittee coordinated the trial and communicated with the spon-
sor (Abbott).
Sample Size and Statistical Methods
Effectiveness Sample Size Determination
For the primary effectiveness end point of HFH rate during 1 
year, 300 patients were estimated to provide >90% power to 
meet the efficacy goal (upper confidence limit less than the 
HF hospitalization rate in the year before enrollment), using a 
1-sample, 2-sided Poisson CI with α of 0.05.
Safety Sample Size Determinations
For the 2-year primary safety end point of freedom from device- 
or system-related complications, using an exact 2-sided test for 
1-sample binomial proportions with α of 0.05, a sample size of 
619 subjects was estimated to provide >90% power to detect 
a difference as small as 5% from the null proportion rate of 
0.80 (ie, objective performance criterion of 80%). For pressure 
sensor failures at 2 years, a sample size of 663 subjects was 
estimated to provide >90% power to detect a difference as 
small as 3.5% from the null proportion rate of 0.90 (ie, objective 
performance criterion of 90%). Thus, the sample size for this 
study was driven by the safety end points. The 2-year attrition 
rate in CHAMPION was 49.1% (228/550).7 To ensure suffi-
cient patients were enrolled to adequately evaluate safety and 
efficacy, 1200 subjects were enrolled. Note that at least 35% 
of the 1200 enrolled patients (420) were planned to be women 
resulting in ≈206 women completing the trial (assuming a 49% 
attrition rate). This sample size was planned to provide >90% 
power to meet the goal for effectiveness. Regarding freedom 
from device- or system-related complications and freedom from 
pressure sensor failures, 206 women would provide >90% 
power to detect a difference as small as 0.06 from the null pro-
portion rate of 0.90.
Statistical Methods
Data were summarized using univariate statistics (eg, N, mean, 
SD) or frequency (eg, N, %) as appropriate. For baseline charac-
teristics and demographics continuous variables were analyzed 
using 2 sample t test, and categorical variables were analyzed 
using the Fisher exact test. Enrollment was defined as having a 
successful pressure sensor implant. The safety population for all 
safety analyses was all subjects who received a pressure sen-
sor implant or underwent the implant procedure but were never 
implanted, regardless of study completion status. The primary 
time point for safety analyses was 24 months, but 12 months 
were available for the 1-year analysis. Safety analysis was per-
formed with a test of binomial proportions against performance 
criteria. The primary time point for effectiveness analyses was 
12 months post enrollment. Unless otherwise specified, all sta-
tistical tests were 2-sided with a significance level of 0.05. The 
effectiveness population consists of all subjects who received a 
pressure sensor implant regardless of study completion status. 
All effectiveness analyses were performed on the effectiveness 
population. Effectiveness end points were analyzed using an 
Andersen-Gill method. Additional details regarding the statisti-
cal methods are shown in the Data Supplement.
RESULTS
Baseline Characteristics
For the cohort of 1200 patients, mean age was 
69.4±12 years, 37.7% were women, 14.3% were Black, 
53% had HFrEF (EF <40%), 30% had HFpEF (EF 
>50%), and 17% had HF with mid-range EF (40% ≤ 
EF ≤50%; Table 1). Among those with HFrEF, 94.8% 
were receiving a β-blocker, 68.0% were receiving ACE 
inhibitor/ARB/ARNI (angiotensin receptor–neprily-
sin inhibitor), and 66.4% were receiving both a β-blocker 
and ACE inhibitor/ARB/ARNI. Use of an aldosterone 
agonist in those with HFrEF was 54.6%. Hemodynam-
ics in the cardiac catheterization laboratory at the time 
of sensor implant showed a mean PA diastolic pressure 
of 20.1±7.9 mm Hg and mean cardiac index of 2.2±0.7 
(Table 2). Ambulatory pressure readings during the first 
week at home were higher than at the time of sensor 
implant with a mean PA diastolic pressure of 24.7±8.5 
mm Hg and a mean PA mean pressure of 34.3±10.2 
mm Hg.
Medication Changes
During the study period, 94.1% of patients had a 
change in medications with an average of 1.6 medi-
cation changes per patient per month. Throughout 
the 12-month study, 81.8% of patients had a change 
in medication related to an increase in PA pressure, 
55.8% of patients had a change in medication that 
was related to a decrease in PA pressure and 82.8% of 
Figure 1. Screening and follow-up.
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subjects had a medication change that was unrelated 
to PA pressure, as would be appropriate for uptitration 
of neurohormonal modulation in stable patients. In the 
subgroup of patients with HFrEF (n=637), there was a 
significant increase the proportion of patients receiv-
ing an ARNI at baseline and at 12 months, 16.6% ver-
sus 27.5%, P<0.001.
Pressure Transmission Compliance
A total of 286 777 pressure transmissions were col-
lected during the study period. Mean and median daily 
pressure transmissions were 76±24% and 85%, respec-
tively. Mean and median weekly pressure transmission 
were 93±16% and 100%, respectively. Median daily 
pressure transmission decreased from 97% at 1 month 
to 85% at 12 months. Median weekly pressure transmis-
sion remained 100% over the study period.
Net PA Pressure Change
For the entire cohort of patients, PA pressures declined 
significantly from baseline during the 1 year of obser-
vation (AUC, −790.9±2097.0 mm Hg days); however, 
the pattern of PA pressure change differed according 
to baseline mean PA pressures at the time of sen-
sor implantation. Figure 2 shows mean PA pressure 
changes for patients stratified by their baseline mean 
PA pressures. For patients with a baseline mean PA 
pressure <25 mm Hg (n=211), the AUC was posi-
tive (499.3±2005.0); mean PA pressure at baseline 
was 20.2±4.9 mm Hg, which increased by 1.5±5.8 
mm Hg at the end of the first year (P<0.0002). For 
patients with a baseline mean PA pressure between 
25 and 35 mm Hg (n=435), the AUC was negative 
(−444.1±1643.7); mean PA pressure at baseline was 
30.2±2.8 mm Hg, which decreased by 1.3±5.0 mm Hg 
at the end of the first year (P<0.0001). For patients 
with baseline mean PA pressure ≥35 mm Hg (n=550), 
Table 1. Baseline Characteristics
All Patients* EF <40% 40%≤ EF ≤50% EF >50%
n=1200 n=637 n=198 n=363
Age, mean (SD), y 69 (12) 67 (13) 71 (11) 72 (10)
Men 748 (62.3) 454 (71.3) 123 (62.1) 169 (46.6)
Women 452 (37.7) 183 (28.7) 75 (37.9) 194 (53.4)
Race/ethnicity
 White 993 (82.8) 499 (78.3) 171 (86.8) 321 (88.4)
 Black 172 (14.3) 114 (17.9) 26 (13.2) 32 (8.8)
 Asian 12 (1.0) 8 (1.3) 0 (0) 4 (1.1)
 Other 18 (1.5) 14 (2.2) 0 (0) 4 (1.1)
Body mass index, mean (SD), kg/m2 31.7 (7.9) 30.2 (7.5) 31.7 (7.7) 34.2 (8.0)
Ischemic cardiomyopathy 496 (41.3) 352 (55.3) 78 (39.4) 64 (17.6)
CRT or CRT-D device 239 (19.9) 189 (29.7) 36 (18.2) 13 (3.6)
ICD device 387 (32.3) 323 (50.7) 39 (19.7) 25 (6.9)
Comorbidities
 Hypertension 1049 (87.4) 538 (84.5) 180 (90.9) 329 (90.6)
 Coronary artery disease 792 (66.0) 452 (71.0) 136 (68.7) 202(55.6)
 Diabetes mellitus 655 (54.6) 338 (53.1) 108 (54.5) 207 (57.0)
 Chronic obstructive pulmonary disease 422 (35.2) 201 (31.6) 74 (37.4) 146 (40.2)
 Chronic kidney disease, stage 3 694 (57.8) 358 (56.2) 114 (57.6) 221 (60.9)
 Chronic kidney disease, stage 4 114 (9.5) 55 (8.6) 19 (9.6) 40 (11.0)
Medical therapy
 β-blocker 1057(88.1) 604 (94.8) 174 (87.9) 277 (76.3)
 ACE inhibitor/ARB/ARNI 683 (56.9) 433 (68.0) 114 (57.6) 135 (37.2)
 β-blocker + ACE inhibitor/ARB/ARNI 636 (53.0) 423 (66.4) 104 (52.5) 108 (29.8)
 Aldosterone agonist 529 (44.1) 348 (54.6) 77 (38.9) 103 (28.4)
 Loop diuretic 1148 (95.7) 605 (95.0) 188 (94.9) 353 (97.2)
Glomerular filtration rate, mL/min per 1.73 m2 53.2 (21.1) 55.0 (22.0) 53.3 (20.9) 50.0 (19.2)
ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CRT, cardiac 
resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillation; EF, ejection fraction; and ICD, implantable cardiac defibrillator.
*Two subjects had missing ejection fraction values at study entry.
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the AUC was 3-fold more negative (−1560.2±2137.7); 
mean PA pressure at baseline was 43.0±6.8 mm Hg, 
which decreased by 4.8±6.2 mm Hg at the end of the 
first year (P<0.0001).
Primary Effectiveness Outcome
The rate of HFH was significantly lower in the 1-year post-
implant compared with the 1-year preimplant. There were 
1600 HFH (1.25 events/patient-years before) compared 
with 628 HFH (0.54 events/patient-years after implant) 
resulting in a risk reduction of 57% (hazard ratio [HR] 0.43 
[95% CI, 0.39–0.47]; P<0.0001; Figure 3A). The rate of 
HFH was significantly lower in the 1-year postimplant com-
pared with the 1-year preimplant in those who survived to 1 
year (HR, 0.35 [95% CI, 0.31–0.39]; P<0.0001). Survival at 
1-year postimplant was 83.9% (95% CI, 81.7%–85.9%), 
and there were significant baseline differences in disease 
severity of patients who survived to 1 year compared with 
those who died (Table I in the Data Supplement). The rate 
of ACH was also significantly lower in the 1-year postim-
plant compared with the 1-year preimplant (Figure 3B). 
There were 2918 ACH (2.28 events/patient-years) com-
pared with 1932 ACH (1.67 events/patient-years) result-
ing in a significant risk reduction of 27% (HR, 0.73 [95% 
CI, 0.68–0.78]; P<0.0001). Lower HFH rates in the 1-year 
postimplant compared with the 1-year pre implant were 
consistent among all EF ranges (EF <40%, 40% ≤ EF ≤ 
50%, and EF >50%; Figure 3C). Prespecified subgroups 
defined by gender, race (Black and White), ischemic or 
nonischemic cause, presence/absence of implantable car-
diac defibrillator, or cardiac resynchronization therapy defi-
brillator all had lower HFH postimplant compared with the 
1-year preimplant (Figure 4). In the subgroup of patients 
with HFrEF, HFH postimplant compared with the year pre-
implant was lower, regardless of the intensity of baseline 
medical therapy. For the entire HFrEF cohort (n=637), 
there were 907 HFH (1.33 events/patient-years) before 
compared with 377 HFH (0.61 events/patient-years) after 
implant, resulting in a risk reduction of 54% (HR, 0.46 
[95% CI, 0.40–0.52]; P<0.0001). For patients with HFrEF 
receiving both an ACE inhibitor/ARB/ARNI and β-blocker 
at study entry (n=423), there were 546 HFH (1.21 
events/patient-years) before compared with 221 HFH 
(0.53 events/patient-years) after implant, resulting in a 
risk reduction of 56% (HR, 0.44 [95% CI, 0.37–0.52]; 
P<0.0001). Lower HFH rates in the year postimplant com-
pared with the year preimplant were consistent regardless 
of baseline PA pressures (Table II in the Data Supple-
ment). When stratifying patients based upon the number of 
HFH events before study enrollment (<2, 2–4, and ≥5), all 
groups had fewer events in the year postimplant (Table III 
in the Data Supplement). It was not possible to distinguish 
from baseline characteristics a group of patients who were 
unlikely to derive benefit from PA pressure-guided therapy. 
PA pressures decreased from baseline after device implan-
tation even in patients who died during the first year. Only 
47 of the 1200 patients (3.9%) experienced 2 or more 
HFH in the year postimplant compared with their previ-
ous year, in whom the baseline characteristics were similar, 
including the rate of β-blocker use and renin-angioten-
sin-aldosterone system (RAAS) inhibition, compared with 
patients who experienced <2 HFH in the year postim-
plant compared with their previous year.
Safety End Points
There were 5 device- or system-related complications 
(0.4%); freedom from device- or system-related com-
plications was 99.6%. There was one pressure sensor 
failure (0.1%); freedom from pressure sensor failure was 
Table 2. Baseline Hemodynamics at Sensor Implant and Ambulatory Hemodynamics During First Week
All Patients* EF <40% 40%≤ EF ≤50% EF >50%
n=1200 n=637 n=198 n=363
Baseline hemodynamics at sensor implant
 Systolic blood pressure, mm Hg 126.6 (22.1) 121.2 (19.9) 129.9 (24.5) 134.1 (21.7)
 Heart rate (bpm) 73.9 (12.4) 75.1 (12.2) 71.6 (12.7) 72.9 (12.5)
 Pulmonary capillary wedge pressure, mm Hg 19.7 (8.4) 20.6 (9.1) 18.4 (6.8) 18.8 (7.5)
 Pulmonary artery systolic pressure, mm Hg 48.0 (14.9) 48.1 (15.2) 45.2 (13.7) 49.4 (14.7)
 Pulmonary artery diastolic pressure, mm Hg 20.1 (7.9) 20.5 (8.4) 18.9 (7.1) 19.8 (7.1)
 Pulmonary artery mean pressure, mm Hg 31.3 (9.9) 31.6 (10.5) 29.4 (8.6) 31.9 (9.2)
 Cardiac index, L/min per m2 2.2 (0.7) 2.1 (0.7) 2.3 (0.7) 2.4 (0.8)
Ambulatory hemodynamics during first week
 Pulmonary artery systolic pressure, mm Hg 49.0 (13.8) 49.0 (13.6) 47.9 (13.1) 49.7 (14.4)
 Pulmonary artery diastolic pressure, mm Hg 24.7 (8.5) 25.6 (8.5) 23.8 (7.2) 23.8 (8.9)
 Pulmonary artery mean pressure, mm Hg 34.3 (10.2) 34.8 (10.2) 33.4 (9.3) 34.1 (10.7)
EF indicates ejection fraction.
*Two subjects had missing ejection fraction values at study entry.
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99.9%. Both rates exceeded the prespecified objective 
performance criteria.
DISCUSSION
The CardioMEMS Post-Approval Study represents the 
largest evaluation of PA pressure-guided therapy in rou-
tine clinical practice. During the year following implan-
tation of the PA pressure sensor, HFH and ACH were 
significantly lower compared with the year prior, with risk 
reductions comparable to those seen in the randomized 
trial which led to Federal Drug Agency approval of the 
device for commercial use.7 Reductions were seen con-
sistently across subgroups for which questions remained 
after the CHAMPION trial, including those defined by 
sex, race, age, EF range, HF cause, and use of implanted 
cardiac rhythm devices. Furthermore, decreased HFH 
rates were seen regardless of baseline PA pressures. 
Rates of device related complications and pressure sen-
sor failure were low and well below the objective perfor-
mance criteria at 1-year set by the CHAMPION trial.7 
These data support the real-world effectiveness of PA 
pressure-guided therapy in clinical practice across a 
broad range of patients with symptomatic HF and prior 
HFH.
The study cohort experienced significant reduc-
tions in PA pressures, with the largest reduction seen in 
patients with higher baseline PA pressures. The ability to 
Figure 2. Change in pulmonary artery 
pressure over time.
Figure 3. Heart failure hospitalization (HFH) and all-cause hospitalization (ACH) rates 1-year preimplant and 1-year postimplant.
A, HFH rate 1-year preimplant and 1-year postimplant. B, ACH rate 1-year preimplant and 1-year postimplant. C, HFH rate 1-year preimplant 
and 1-year postimplant stratified by ejection fraction (EF) ranges (EF<40%, 40%≤ EF ≤50%, and EF>50%).
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continuously monitor PA pressures and adjust medical 
therapy allowed clinicians to optimize volume status in 
the ambulatory setting. Prior studies have suggested that 
there is a significant benefit for maintaining small reduc-
tions in cardiac pressures over extended periods of time.6 
The reduction in ACH in the current CardioMEMS Post-
Approval Study is also consistent with prior findings from 
the CHAMPION study.7 This may reflect the benefit of 
optimal volume status and lower pulmonary pressures for 
other major medical conditions, such as chronic obstruc-
tive pulmonary disease, a common comorbidity in patients 
with advanced HF.12 In a subgroup of 187 patients from 
the CHAMPION study with chronic obstructive pulmo-
nary disease, patients randomized to PA pressure-guided 
therapy had a 41% reduction in HFH and a 62% reduc-
tion in respiratory related hospitalizations.13
Similar to the CHAMPION study, we found a low 
rate of procedural and device related complications.7 
Freedom from device- or system-related complications 
and freedom from pressure sensor failure were high. 
These findings are important as the CardioMEMS Post-
Approval Study was performed at 104 clinical sites within 
the United States and included both academic and non-
academic sites. These observations are reassuring and 
confirm that this technology and strategy can be safely 
used in routine clinical practice settings.
At study entry, use of guideline-directed medical therapy 
for those with HFrEF was similar to contemporary HF stud-
ies of symptomatic HF including the COAPT (Cardiovascu-
lar Outcomes Assessment of the MitraClip Percutaneous 
Therapy for Heart Failure Patients With Functional Mitral 
Regurgitation), IMPROVE-HF (Registry to Improve the Use 
of Evidence-Based Heart Failure Therapies in the Outpa-
tient Setting), and CHAMP-HF (Change the Management 
of Patients With Heart Failure) Registry.14–16 The benefits 
of PA pressure-guided therapy were seen in addition to 
optimal medical therapy. Prior studies of remote hemo-
dynamic monitoring, including COMPASS-HF (Chronicle 
Offers Management to Patients With Advanced Signs and 
Symptoms of Heart Failure), found the greatest reduc-
tion in hospitalizations and also found decreased mortal-
ity when pulmonary pressure-guided therapy was used in 
patients already receiving optimal medical therapy.3,15
We included patients with a wide range of EF, including 
17% with mid-range EF and 30% with HFpEF. Patients 
with mid-range EF represent a unique HF subgroup and 
in the current study were receiving relatively high doses 
of guideline-directed medical therapy and also derived 
benefit from PA pressure-guided therapy.17,18 Treatment 
options for patients with HFpEF remain limited.17–19 This 
study of 363 patients with HFpEF confirms the benefit 
shown for the patients with HFpEF in the CHAMPION 
study, PA pressure-guided therapy is the first intervention 
proven to decrease HFH in this growing population.7,20
The benefits of PA pressure-guided therapy in the 
CardioMEMS Post-Approval Study were seen across all 
patient subgroups, including women, Blacks, and those 
with or without implantable cardiac defibrillator and car-
diac resynchronization therapy defibrillator devices, all of 
whom were better represented in this study than in the 
pivotal CHAMPION trial. These analyses demonstrate 
that this strategy, and this device can be broadly applied 
to improve outcomes in routine clinical practice.
Limitations
By design, this Post-Approval Study was a single-arm 
study comparing patients before and after enrollment 
with no randomized control group. There was likely 
underestimation of HFH events before enrollment due 
Figure 4. Heart failure hospitalization (HFH) rate 1-year preimplant and 1-year postimplant in prespecified subgroups.
CRT-D indicates cardiac resynchronization therapy defibrillation; HFH, heart failure hospitalization; HR, hazard ratio; and ICD, implantable 
cardiac defibrillator.
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to incomplete recall of events (information bias).21 This 
factor would have decreased the ability to detect benefit 
from the intervention, after which all events were pro-
spectively reported. Censoring at the time of death may 
have resulted in survivor bias; however, patients who died 
did contribute 89 patient-years to the follow-up after 
device implant. The CardioMEMS Post-Approval Study 
enrolled high-risk patients with mortality comparable to 
that seen in the contemporary HF trials.4,5,22 The preim-
plant risk of HFH in the CardioMEMS Post-Approval 
Study was ≈2-fold higher than those enrolled in the 
open-access study8 after the randomized period of the 
CHAMPION trial. Despite the higher baseline risk in the 
CardioMEMS Post-Approval Study population, we found 
comparable reduction in hospitalizations between this 
study, CHAMPION, and the open-access studies.7,8
Conclusions
In summary, we found that both HF hospitalizations and 
all-cause hospitalizations were significantly lower in the 
year following implantation of a PA pressure sensor to 
guide HF management. The magnitude of decrease in 
PA pressures was related to baseline PA pressures, with 
greatest reductions in those with the highest pressures 
at baseline. Reductions in HF hospitalization were con-
sistent across sex and race, across all EF ranges and 
in addition to best medical and rhythm device therapy. 
PA pressure-guided therapy was safe with few device- 
or system-related complications and a low rate of pres-
sure sensor failure. These findings are consistent with 
the previous randomized trial data in demonstrating that 
PA pressure-guided therapy can effectively and safely 
improve outcomes in all major subgroups of HF, includ-
ing patients with preserved EF, and support the efficacy 
of hemodynamic-guided therapy in clinical practice.
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